1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Medite Cancer Diagnostics, Inc.

Medite Cancer Diagnostics, Inc.

MDIT
Medite Cancer Diagnostics, Inc.US flagOther OTC
0.00
USD
- -
- -
8,672.00Market Cap
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
TTM
Revenue per Share
1.06
0.39
0.24
0.31
0.11
0.07
0.04
0.27
0.68
0.61
0.49
0.43
0.26
0.15
Basic EPS, GAAP
-45.52
-30.07
-24.06
-15.97
-9.12
-5.17
-5.4
-2.46
-0.01
-0.04
-0.05
-0.11
-0.26
-0.1
Free Cash Flow per Basic Share
-12.39
-22.66
-17.56
-18.15
-4.05
-2.53
-1.23
-0.95
-0.03
-0.07
-0.03
-0.06
-0.14
-0.1
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-633.93
-318.34
-249.21
-229.49
-227.6
-213.18
-172.33
-141
0.16
0.09
0.04
-0.06
-0.31
-0.19
Tangible Book Value per Share
-161.63
-26.32
-14.26
-2.99
-8.76
-11.59
-13.15
-12.13
0.18
-0.2
-0.11
-0.16
-0.22
-0.09
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
1
1
15
18
20
21
26
56
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
10
11
10
9
7
8
Operating Margin (%)
-982.91
-5,048.94
-9,451.81
-5,097.6
-7,490.91
-6,170
-8,033.33
-640.91
2.95
-3.59
-6.06
-17.98
-95.11
-49.34
Depreciation Expense
3
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-4
-7
-8
-6
-4
-2
-3
-2
- -
-1
-1
-2
-7
-5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
26.03
- -
- -
- -
- -
- -
Profit Margin (%)
-3,697.44
-6,985.11
-9,540.96
-5,062.4
-8,072.73
-6,990
-11,983.33
-764.65
0.54
-6.36
-8.69
-23.41
-99.97
-65.49
Working Capital
-10
-3
-4
-2
-4
-6
-7
-7
2
-1
-1
-2
- -
1
LT Debt
- -
1
- -
- -
- -
- -
- -
- -
2
1
1
- -
5
5
Total Equity
-10
-3
-3
- -
-2
-4
-6
-7
3
8
9
8
6
6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
101.86
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-0.61
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-40.31
-76.27
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'18
Jun'18
Sep'18
ST Debt
- -
- -
1
LT Borrowings
5
5
5
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
1
1
1
Shares Outstanding
48
61
75
Market Capitalization
5
8
11

Working Capital

FRC

•

in mil. unless spec.
Mar'18
Jun'18
Sep'18
Total Current Assets
4
4
5
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
1
1
1
Inventories
3
3
4
Total Current Liabilities
4
4
5
Payables & Accruals
3
3
4
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-53.06%
10.69%
-28.02%
Free Cash Flow
26.72%
79.52%
207.05%
Net Income, GAAP
-122.36%
-221.69%
214.89%
Sales/Revenue/Turnover
555.58%
979.36%
-26.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
2
3
2
2
9
2017
2
1
2
2
7
2018
2
2
2
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-0.03
-0.01
-0.02
- -
-0.11
2017
-0.04
-0.06
-0.06
- -
-0.26
2018
-0.04
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Rahsan-Rahsan Lindsay
Full Time Employees
69
Sector
Healthcare
Industry
Medical - Specialties
Address
10524 Moss Park Road Orlando FL United States of America 32832
IPO Date
Feb 1, 1995
Website
medite-group.com
Similar Companies
SmileDirectClub Inc Class A (SDCCQ)
Jiangsu Hanvo Safety Product Co., Ltd. (300952.SZ)
Masimo Corporation (0JZ2.L)
DRTECH Corporation (214680.KQ)
InBody Co.,Ltd (041830.KQ)
Novateor Research Laboratories (NOVATEOR.BO)
Business
Medite Cancer Diagnostics, Inc. operates as a medical technology company specializing in the development, manufacture, and marketing of molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions along with related diseases. Its core product portfolio includes a range of histology laboratory instruments such as the USE 33 ultrasonic decalcification instrument, TPC 15 Duo and Trio tissue processing instruments, TES 99 and TES Valida cooling units, and various microtomes including M530, A550, M380, and the M630 freezing microtome for tissue sectioning. The company also offers advanced staining and coverslipping systems like the TST44 robotic multi-staining system, COT 20 linear staining system, and robotic coverslippers RCM 9000, ACS 720, and TWISTER. Additionally, Medite develops the SoftKit device, designed for self-collection of samples to enable health assessments of the female genital tract. Founded as CytoCore, Inc. and rebranded to Medite Cancer Diagnostics, Inc. following its acquisition by Medite Group in 2014, the company strategically focuses on histology and cytology cancer diagnostic instruments and consumables used worldwide in laboratories that conduct cancer screening and diagnosis. Its operational presence is primarily in the United States, with products marketed to clinical laboratories and medical institutions engaged in cancer diagnostics. Recent company updates indicate no major new partnerships or acquisitions reported in the past two years; however, Medite continues to innovate within its product line, maintaining focus on enhancing diagnostic capabilities for cancer detection with an emphasis on molecular biomarkers and automated laboratory instruments. The company also maintains strategic development in the proteomic-based screening methods for endometrial and cervical cancers while expanding its application scope to gastrointestinal and other cancers. Medite Cancer Diagnostics operates as a single-segment company within the medical technology and diagnostic devices industry, targeting healthcare providers, pathology laboratories, and cancer research institutions. It is headquartered in the United States and continues to expand its technological offerings in histology and cytology to support early and accurate cancer detection globally.